http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 21 Oct 2026 10:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Absci+Corp.+%28ABSI%29/27206258.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $16.00 price target on Absci Corp. (NASDAQ: ABSI).</p><p>The analyst commented: "On October 19, Veradermics (MANE; not rated) reported Part A topline data from Study 304 (print; slides), its second registration-directed trial of VDPHL01, an extended-release oral minoxidil, in 536 men with mild-to-moderate pattern hair loss (PHL) randomized to VDPHL01 8.5mg once daily (QD; n=178), VDPHL01 8.5mg twice daily (BID; n=177) or twice-daily placebo (n=181). On the standard regulatory approval endpoint, the change in non-vellus target area hair count (TAHC) from baseline to Month 6, VDPHL01 increased TAHC by 28.6 hairs/cm² http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Absci+Corp.+%28ABSI%29/27206258.html Tue, 20 Oct 2026 06:50:13 -0400 ABSI http://www.streetinsider.com/Analyst+PT+Change/Absci+Corp.+%28ABSI%29+PT+Raised+to+%2420+at+KeyBanc/27196256.html KeyBanc analyst Scott Schoenhaus raised the price target on Absci Corp. (NASDAQ: ABSI) to $20.00 (from $16.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Absci+Corp.+%28ABSI%29+PT+Raised+to+%2420+at+KeyBanc/27196256.html Fri, 16 Oct 2026 09:11:27 -0400 ABSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+McClain+Sean/27188159.html si-local-file:///var/storage/secattach/20261014/27188159.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+McClain+Sean/27188159.html Wed, 14 Oct 2026 19:16:00 -0400 ABSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Bedrick+Todd/27188158.html si-local-file:///var/storage/secattach/20261014/27188158.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Bedrick+Todd/27188158.html Wed, 14 Oct 2026 19:16:00 -0400 ABSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Jonasson+Zachariah/27188156.html si-local-file:///var/storage/secattach/20261014/27188156.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Jonasson+Zachariah/27188156.html Wed, 14 Oct 2026 19:15:00 -0400 ABSI http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY